- Tytuł:
- Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer.
- Autorzy:
- Źródło:
- FEBS letters [FEBS Lett] 2022 Mar; Vol. 596 (5), pp. 557-566. Date of Electronic Publication: 2021 Nov 12.
- Typ publikacji:
- Journal Article; Research Support, Non-U.S. Gov't; Review
- Język:
- English
- Imprint Name(s):
-
Publication: Jan. 2016- : West Sussex : John Wiley & Sons Ltd.
Original Publication: Amsterdam, North-Holland on behalf of the Federation of European Biochemical Societies. - MeSH Terms:
-
Interleukin-6*/metabolism
Neoplasms*/genetics
Animals ; Cytokine Receptor gp130/genetics ; Cytokine Receptor gp130/metabolism ; Cytokines/metabolism ; Inflammation/metabolism ; Mice ; Receptors, Interleukin-6/metabolism - References:
-
Rose-John S, Winthrop K and Calabrese L (2017) The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol 13, 399-409.
Rose-John S (2018) Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol 10, a028415.
Garbers C, Heink S, Korn T and Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17, 395-412.
Schaper F and Rose-John S (2015) Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 26, 475-487.
Kang S, Tanaka T, Narazaki M and Kishimoto T (2019) Targeting interleukin-6 signaling in clinic. Immunity 50, 1007-1023.
Wilkinson AN, Gartlan KH, Kelly G, Samson LD, Olver SD, Avery J, Zomerdijk N, Tey SK, Lee JS, Vuckovic S et al. (2018) Granulocytes are unresponsive to IL-6 due to an absence of gp130. J Immunol 200, 3547-3555.
Hunter CA and Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16, 448-457.
Jones SA and Jenkins BJ (2018) Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18, 773-789.
Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC and Rose-John S (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23, 473-480.
Riethmueller S, Somasundaram P, Ehlers JC, Hung CW, Flynn CM, Lokau J, Agthe M, Dusterhoft S, Zhu Y, Grotzinger J et al. (2017) Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biol 15, e2000080.
Mullberg J, Althoff K, Jostock T and Rose-John S (2000) The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 11, 27-38.
Scheller J, Chalaris A, Garbers C and Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32, 380-387.
Rose-John S and Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300(Pt 2), 281-290.
Jones SA, Scheller J and Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121, 3375-3383.
Baumann H and Gauldie J (1994) The acute phase response. Immunol Today 15, 74-80.
Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813, 878-888.
Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Volk V, Mishra N, Blase JI, Nikolaus N et al. (2021) Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 160, 2354-2366.
Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J and Rose-John S (1997) I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15, 142-145.
Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23, 1-21.
Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF and Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268, 160-167.
Thilakasiri P, Huynh J, Poh AR, Tan CW, Nero TL, Tran K, Parslow AC, Afshar-Sterle S, Baloyan D, Hannan NJ et al. (2019) Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. EMBO Mol Med 11, e9539.
Nayar S, Morrison JK, Giri M, Gettler K, Chuang LS, Walker LA, Ko HM, Kenigsberg E, Kugathasan S, Merad M et al. (2021) A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease. Nature 593, 275-281.
Stuhlmann-Laeisz C, Lang S, Chalaris A, Krzysztof P, Enge S, Eichler J, Klingmuller U, Samuel M, Ernst M, Rose-John S et al. (2006) Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell 17, 2986-2995.
Scherger AK, Al-Maarri M, Maurer HC, Schick M, Maurer S, Ollinger R, Gonzalez-Menendez I, Martella M, Thaler M, Pechloff K et al. (2019) Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight 4, e128435.
Heinrich PC, Castell JV and Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265, 621-636.
Gabay C and Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340, 448-454.
Vermeire S, Van Assche G and Rutgeerts P (2005) The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2, 580-586.
Uhlar CM and Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265, 501-523.
Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X et al. (2019) Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249-252.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL and Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238.
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189.
Honda K and Littman DR (2016) The microbiota in adaptive immune homeostasis and disease. Nature 535, 75-84.
Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, Lin WY, Yeung ST, Silva HM, Li D et al. (2020) Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell 183, 2036-2039.
Whitcomb DC (2006) Clinical practice. Acute pancreatitis. N Engl J Med 354, 2142-2150.
Bone RC (1991) Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 114, 332-333.
Zhang H, Neuhofer P, Song L, Rabe B, Lesina M, Kurkowski MU, Treiber M, Wartmann T, Regner S, Thorlacius H et al. (2013) IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest 123, 1019-1031.
Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, Ruckauer K, Andreesen R, Farthmann EH and Scholmerich J (1991) Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 101, 782-785.
Algul H, Treiber M, Lesina M, Nakhai H, Saur D, Geisler F, Pfeifer A, Paxian S and Schmid RM (2007) Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Invest 117, 1490-1501.
Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H and Kohler G (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342.
Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S and Scheller J (2008) Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111, 1021-1028.
Rose-John S (2017) The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin Pharmacol Ther 102, 591-598.
Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen KJ et al. (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278, 38829-38839.
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733.
Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P and Blobel CP (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164, 769-779.
Zunke F and Rose-John S (2017) The shedding protease ADAM17: physiology and pathophysiology. Biochim Biophys Acta Mol Cell Res 1864, 2059-2070.
Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN et al. (1998) An essential role for ectodomain shedding in mammalian development. Science 282, 1281-1284.
Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y and Blobel CP (2007) Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 179, 2686-2689.
Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S et al. (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207, 1617-1624.
Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M et al. (2014) EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol 16, 972-977.
Bergmann J, Muller M, Baumann N, Reichert M, Heneweer C, Bolik J, Lucke K, Gruber S, Carambia A, Boretius S et al. (2017) IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 65, 89-103.
Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, Diamanti MA, Linder M, Timelthaler G, Dienes HP et al. (2017) EGFR in tumor-associated myeloid cells promotes development of colorectal cancer in mice and associates with outcomes of patients. Gastroenterology 153, 178-190 e10.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113.
Spehlmann ME, Manthey CF, Dann SM, Hanson E, Sandhu SS, Liu LY, Abdelmalak FK, Diamanti MA, Retzlaff K, Scheller J et al. (2013) Trp53 deficiency protects against acute intestinal inflammation. J Immunol 191, 837-847.
Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knosel T et al. (2018) ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. J Exp Med 215, 1205-1225.
Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF et al. (2003) Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762-777.
Schumacher N, Meyer D, Mauermann A, von der Heyde J, Wolf J, Schwarz J, Knittler K, Murphy G, Michalek M, Garbers C et al. (2015) Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles. J Biol Chem 290, 26059-26071.
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S et al. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501.
Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S and Bardelli A (2014) Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 8, 1084-1094.
Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY et al. (2021) Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373, eabj0486.
Kefaloyianni E, Muthu ML, Kaeppler J, Sun X, Sabbisetti V, Chalaris A, Rose-John S, Wong E, Sagi I, Waikar SS et al. (2016) ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight 1, e87023.
Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z et al. (2019) ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol Med 11, e9976.
Saad MI, McLeod L, Hodges C, Vlahos R, Rose-John S, Ruwanpura S and Jenkins BJ (2021) ADAM17 deficiency protects against pulmonary emphysema. Am J Respir Cell Mol Biol 64, 183-195.
Nicolaou A, Zhao Z, Northoff BH, Sass K, Herbst A, Kohlmaier A, Chalaris A, Wolfrum C, Weber C, Steffens S et al. (2017) Adam17 deficiency promotes atherosclerosis by enhanced TNFR2 signaling in mice. Arterioscler Thromb Vasc Biol 37, 247-257.
Patel N, Herrman JM, Timans JC and Kastelein RA (1996) Functional replacement of cytokine receptor extracellular domains by leucine zippers. J Biol Chem 271, 30386-30391.
Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M and Rogers D (1988) Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 336, 688-690.
Viswanathan S, Benatar T, Rose-John S, Lauffenburger DA and Zandstra PW (2002) Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells 20, 119-138.
Dechow T, Steidle S, Gotze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V et al. (2014) GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 124, 5263-5274.
Schumacher N, Yan K, Gandrass M, Muller M, Krisp C, Hasler R, Carambia A, Nofer JR, Bernardes JP, Khouja M et al. (2021) Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice. J Hepatol 74, 407-418. - Contributed Indexing:
- Keywords: cancer; inflammation; interleukin-6; pancreatitis; trans-signaling
- Substance Nomenclature:
-
0 (Cytokines)
0 (Interleukin-6)
0 (Receptors, Interleukin-6)
133483-10-0 (Cytokine Receptor gp130) - Entry Date(s):
- Date Created: 20211105 Date Completed: 20220503 Latest Revision: 20220503
- Update Code:
- 20240105
- DOI:
- 10.1002/1873-3468.14220
- PMID:
- 34738234
- Czasopismo naukowe
Menu główne
Wyszukiwarka
Treść główna
